Tumor Necrosis Factor-a Promoter Polymorphism at Position --308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection.

MLA

Chia-yen Dai, et al. “Tumor Necrosis Factor-a Promoter Polymorphism at Position --308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection.” Journal of Infectious Diseases, vol. 193, no. 1, Jan. 2006, pp. 98–101. EBSCOhost, https://doi.org/10.1086/498244.

APA

Chia-yen Dai, Wan-Long Chuang, Wen-Yu Chang, Shinn-cherng Chen, Li-Po Lee, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Jee-Fu Huang, Ming-Yuh Hsieh, Liang-Yen Wang, & Ming-Lung Yu. (2006). Tumor Necrosis Factor-a Promoter Polymorphism at Position --308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection. In Journal of Infectious Diseases (Vol. 193, Issue 1, pp. 98–101). https://doi.org/10.1086/498244

Chicago

Chia-yen Dai, Wan-Long Chuang, Wen-Yu Chang, Shinn-cherng Chen, Li-Po Lee, Ming-Yen Hsieh, Nai-Jen Hou, et al. 2006. “Tumor Necrosis Factor-a Promoter Polymorphism at Position --308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection.” Journal of Infectious Diseases. Vol. 193. doi:10.1086/498244.